Feb 13, 2026
Recent medical updates highlight the long-term health benefits
of the universal hepatitis B birth dose, alongside FDA milestones
including the approval of Optune Pax for pancreatic cancer and a
pembrolizumab-based regimen for platinum-resistant ovarian cancer,
and the granting of priority review to oveporexton for narcolepsy
type 1.